Idiopathic pulmonary fibrosis digest - 2021

Idiopathic pulmonary fibrosis digest - 2021

FDA granted Fast Track Designation for IM156

IM156 (Protein Complex 1 (PC1) inhibitor) – ImmunoMet Therapeutics

  • ImmunoMet was granted fast track designation by the FDA for IM156 in idiopathic pulmonary fibrosis
  • IM156 targets the oxidative phosphorylation (OXPHOS) pathway, decreasing the supply of energy and anabolic precursors that are required to drive fibrotic disease and tumor growth (For full story click here)

With existing ODD, Fast Track designation is another important milestone for ImmunoMet with the potential to quickly advance IM156

Share this

Facebook
fb-share-icon
Twitter
Tweet
LinkedIn
Share

CI Scientists Commentary:

  • This FTD comes within two months of the FDA’s IND clearance and orphan drug designation for IM156. Pre-clinical studies have demonstrated a strong anti-fibrotic effect in animal models of fibrosis
  • Phase 1 data in healthy volunteers is anticipated in 2021, which will inform the design of the Phase 2 trial in patients with IPF
  • With $7.0M in financing in Feb’21 along with these designations, ImmunoMet may develop IM156 faster

– Dr. Kowndinya, CI Scientists

Home